stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Revenue
Trulieve Cannabis Corp.'s revenue for fiscal 2025 was $1.2B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.1B. Over the past ten years it has ranged from $521.5M (fiscal 2020) to $1.2B (fiscal 2022); the current reading is higher than 67% of that period. Trulieve Cannabis Corp. ranks 19th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.2B | (0.45%) |
| FY2024 | $1.2B | 5.07% |
| FY2023 | $1.1B | (7.31%) |
| FY2022 | $1.2B | 30.72% |
| FY2021 | $931.9M | 78.69% |
| FY2020 | $521.5M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $230.2M | (15.03%) |
| Jun 2026 | $271.0M | (5.51%) |
| Mar 2026 | $286.8M | (2.18%) |
| Dec 2025 | $293.1M | 1.72% |
| 19 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. | $1.1B |
| ANIP ANI Pharmaceuticals, Inc. compare | $1.0B |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $961.5M |
| XERS Xeris Biopharma Holdings, Inc. compare | $368.3M |
| ALVO Alvotech compare | $293.3M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TRLV
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement